The patent entitled ‘Sustained-Release Bupropion and Bupropion/Mecamylamine Tablets’ discloses the formulation of pharmaceutical tablets containing sustained-release granules of bupropion HCl distributed in a sustained-release matrix.
Horst Zerbe, president and CEO of IntelGenx, said: “This Notice of Allowance demonstrates IntelGenx’s ability to successfully develop and patent novel products through our proprietary VersaTab technology.
“We believe CPI-300 could fill a significant need in the lucrative bupropion market. With the potential to be the first and only single-tablet high-dose form of bupropion HCl on the market, we believe CPI-300’s convenience and patient compliance advantages could make it a very successful brand.”
The company is currently awaiting approval from the FDA for its New Drug Application (NDA) for CPI-300. IntelGenx and Cary Pharmaceuticals (Cary) entered into a collaborative agreement in November 2007, to jointly develop and commercialise CPI-300 using the former’s proprietary oral VersaTab delivery technology.
Cary serves as the NDA applicant for CPI-300.